[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"overt\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:overt":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100637715",false,"NCT07603817","Association Between Overt and Sub-clinical Primary Hypothyroidism and Metabolic Dysfunction-Associated Steatoic Liver Disease in Non-Diabetic Patients","Association Between Overt and Sub-clinical Primary Hypothyroidism and Metabolic Dysfunction-Associated Steatoic Liver Disease (MASLD) in Non-Diabetic Patients","Inclusion Criteria:\n\n* Patients aged ≥18years old who will be:\n* Diagnosed with primary hypothyroidism (overt or sub clinical hypothyroidism) within 3 months with or without levothyroxine treatment.\n* Patients with positive antibody (positive TPO antibody or positive Thyroglobin antibody) irrespective of thyroid status\n* Metabolic dysfunction-associated steatotic liver disease (MASLD) assessment by ultrasound and Fibro-scan.\n\nExclusion Criteria:\n\n* Diabetic patients according to American Diabetes Association (ADA) Criteria.\n* Excessive Alcohol consumption (\\> 30 gm\u002F day in men, 20 gm \u002Fday in women.\n* Body mass index (BMI) index \\>40 kg\u002Fm2\n* Other causes of chronic hepatic steatosis \\[e.g., positive hepatitis B virus (HBV), positive hepatitis C virus (HCV)), autoimmune disease, Wilson disease, drugs\\].\n* Patients use of drugs known to cause hepatic steatosis (e.g., amiodarone, valproate, tamoxifen, methotrexate, steroids).\n* Treatment with drugs that influence liver fat, as thiazolidinediones, α-glucosidase inhibitors, sodium-glucose -transporter 2 (SGLT2) inhibitors or any glucagon-like peptide-1 receptor agonists during the previous 3 months.\n* Detection of biliary duct obstruction based on imaging studies.\n* Evidence of cirrhosis \\[on basis of ultrasonography and magnetic resonance imaging (MRI )\\] or hepatocellular carcinoma \\[evidence on triphasic Computed Tomography (CT) or MRI\\].\n* Presence of any systemic disease that commonly cause liver disease.\n* Severe hepatic injury and\u002For significant abnormal liver function defined as aspartate aminotransferase \\>5× upper limit of normal (ULN) and\u002For alanine aminotransferase \\>5× ULN or elevated total bilirubin \\> 2 mg\u002Fdl.\n* Pregnant women.\n* Patients with active malignancy.\n* History of bariatric surgery or ongoing weight-loss diet (hypocaloric diet) or use of weight-loss agents unless the diet or treatment has been stopped at least 3 months before screening and that the patient has had a stable body weight (+\u002F- 3 kg) during the 3 months before screening.","ALL","18 Years",{"count":18,"type":19},200,"ESTIMATED","OBSERVATIONAL","This study aims to estimate the prevalence of Metabolic dysfunction - associated Steatoic liver disease (MASLD) among adults with primary hypothyroidism (overt or sub-clinical 1ry hypothyroidism) and prevalence of MASLD in Hashimoto-thyroiditis vs Euthyroid controls in non-diabetic patients.",[23,24,25,26,27],"Overt","Sub-clinical","Primary Hypothyroidism","Metabolic Dysfunction-Associated Steatoic Liver Disease","Non-Diabetic Patients","RECRUITING","2026-05-30",{"date":31,"type":32},"2026-06-02","ACTUAL",{"date":34,"type":32},"2026-03-01",{"date":36,"type":19},"2027-03-01",{"name":38,"class":39},"Sohag University","OTHER",""]